Heartflow, Inc. (NASDAQ:HTFL) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Heartflow, Inc. (NASDAQ:HTFL) have been assigned a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $38.50.

A number of brokerages have recently issued reports on HTFL. Stifel Nicolaus lifted their price target on Heartflow from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. JPMorgan Chase & Co. increased their target price on Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. Canaccord Genuity Group boosted their price objective on shares of Heartflow from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Finally, Wells Fargo & Company assumed coverage on Heartflow in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $38.00 target price for the company.

Heartflow Price Performance

NASDAQ:HTFL opened at $25.99 on Friday. The company has a market cap of $2.21 billion and a PE ratio of -14.36. The business has a 50 day moving average of $30.42. Heartflow has a 12 month low of $25.38 and a 12 month high of $41.22.

Insider Buying and Selling at Heartflow

In related news, Director Jeffrey C. Lightcap acquired 40,000 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The shares were purchased at an average price of $26.34 per share, with a total value of $1,053,600.00. Following the completion of the purchase, the director directly owned 40,000 shares of the company’s stock, valued at $1,053,600. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Institutional Trading of Heartflow

Several hedge funds have recently modified their holdings of HTFL. Baillie Gifford & Co. acquired a new position in Heartflow during the third quarter valued at $101,182,000. Emerald Mutual Fund Advisers Trust purchased a new position in Heartflow in the 3rd quarter valued at $4,418,000. Board of Trustees of The Leland Stanford Junior University acquired a new position in shares of Heartflow during the 3rd quarter worth approximately $10,510,000. Lisanti Capital Growth LLC acquired a new position in Heartflow in the 3rd quarter valued at about $982,000. Finally, TrueMark Investments LLC purchased a new position in shares of Heartflow during the 3rd quarter worth $918,000.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.